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In Table [1](#Tab1){ref-type="table"}, at line 8 after P2Y~14~: "IP3" should be changed to "↓cAMP". Table 1Receptor classification, intracellular signalling, ligands and selective agonists and antagonistsP2 subtypeI.c. signallingLigandSelective agonistSelective antagonistNon-selective antagonistP2Y~1~↑IP3ADP (ATP)MRS2365MRS 2179, MRS2500P2Y~2~↑IP3UTP = ATPMRS2498, UTPγS, INS3717Suramin \> RB2P2Y~4~↑IP3UTP (=ATP In rodents)UTPγS, INS3717--RB2 \> SuraminP2Y~6~↑IP3UDPMRS2666, MRS2633, UDPβSMRS2578P2Y~11~↑IP3, ↑cAMPATPAR-C67085MX, NF546NF157Suramin \> RB2P2Y~12~↓cAMPADP--Clopidogrel, prasugrel, AZD6140, INS50589, AR-C9931 (cangrelor)P2Y~13~↓cAMPADP--MRS2211P2Y~14~↓cAMPUDP-glucose, UDP-galactoseUDP-glucose, UDP-galactose--P2X~1~Positive ion channelATPα,β-mATPNF023, NF449TNP-ATP, Ip~5~IP2X~2~Positive ion channelATP--NF770Suramin, isoPPADS, RB2P2X~3~Positive ion channelATPα,β-mATPA317491, NF110SuraminP2X~4~Positive ion channelATPIvermectin potentiates--TNP-ATPP2X~5~Positive ion channelATP----Suramin, PPADSP2X~6~Positive ion channelATP------P2X~7~Positive ion channelATP--KN62, KN04, MRS2427Coomassie brilliant blue GEctonucleotidaseApyrase, human SolCD39ARC67156

In Fig. [2](#Fig1){ref-type="fig"}, lower left in the VSMC: P2Y~12~ should be P2Y~2~. Fig. 2Functional roles of P2 receptors in the atherosclerotic inflammatory plaque and during restenosis. See text for details. Purines and pyrimidines acting on P2 receptors stimulate vascular inflammation both by actions on the endothelial cell (*EC*) and by effects on inflammatory cells. Furthermore, they stimulate vascular smooth muscle cell (*VSCM*) proliferation, the conversion to synthetic phenotype and production of matrix proteins. Mitogenic P2 receptors are upregulated by growth factors and cytokines. *IL* interleukin, *MCP-1* monocyte chemoattractant protein-1, *ICAM-1* intercellular adhesion molecule-1, *TSP* thrombospondin, *IDO* indoleamine 2,3-dioxygenase
